AGI Therapeutics records losses of €4.3m
IEX-listed gastrointestinal drug products company AGI Therapeutics has announced net losses of €4.3m.
AGI was listed last year on the IEX Market in Dublin and on London's AIM market, raising gross proceeds of €42.5m.